Methylation-Driven Genes Identified as Novel Prognostic Indicators for Thyroid Carcinoma

Area of Science:

• Genomics
• Cancer Biology
• Bioinformatics

Background:

• Aberrant DNA methylation is a key driver in tumorigenesis.
• The specific role of DNA methylation in thyroid cancer development and prognosis is not fully understood.

Purpose of the Study:

• To identify DNA methylation-driven genes in thyroid cancer using integrative bioinformatics.
• To explore the prognostic value of these genes for thyroid cancer patients.

Main Methods:

• Downloaded thyroid cancer transcriptome and DNA methylation data from The Cancer Genome Atlas (TCGA).
• Utilized the methylmix R package to identify methylation-driven genes.
• Performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
• Employed univariate and multivariate Cox regression analyses to build and validate a prognostic multi-gene signature.

Main Results:

• Identified 51 methylation-driven genes significantly enriched in malignancy-related pathways.
• Developed a four-gene signature (RDH5, TREM1, BIRC7, SLC26A7) that accurately predicts patient survival (p < 0.001, ROC AUC = 0.836).
• The signature demonstrated independent prognostic value and was validated in an external cohort.

Conclusions:

• Identified novel methylation-driven genes with independent prognostic value in thyroid cancer.
• These findings offer insights into thyroid cancer's molecular mechanisms.
• The identified gene signature may facilitate personalized treatment strategies for thyroid cancer.